Access Program Information
<p>This is a compassionate use study to allow patients already taking <strong>triheptanoin (C7)</strong> through previous studies to continue to receive the supplement. It will also allow triheptanoin supplementation in patients with qualifying disorders if they are failing conventional therapy.</p>